BioWorld

Jan. 22, 2002

House Committee Investigating ImClone’s Handling Of Erbitux

WASHINGTON A House committee on Friday said it will investigate New York-based ImClone Systems Inc.’s conduct in the development of its well-publicized drug for colorectal cancer. Read More

Pharmacopeia, Eos Scrap Merger Following Shareholder Opposition

Harvard Immunologist, California Firm Join In Hunt For Drugs To Check Human Asthma Onslaught

BIO’s Agenda Includes Quick Appointment Of FDA Leader

Holiday Notice

Other News To Note

Triangle Plans NDA For One Drug, Discontinues Another

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...